phosphorylcholine has been researched along with Neoplasms in 59 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-one patients with advanced neoplasms were treated with monthly cycles of perifosine loading doses of 300, 600, 900, 1,200 and 1,500 mg (dose levels 1 through 5, respectively) on days 1-2 depending on the actual dose of the initial cycle." | 9.19 | A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. ( Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A, 2014) |
| "Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients." | 9.12 | A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. ( Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R, 2006) |
| "Thirty-one patients with advanced neoplasms were treated with monthly cycles of perifosine loading doses of 300, 600, 900, 1,200 and 1,500 mg (dose levels 1 through 5, respectively) on days 1-2 depending on the actual dose of the initial cycle." | 5.19 | A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. ( Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A, 2014) |
| "Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients." | 5.12 | A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. ( Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R, 2006) |
| "Oral perifosine was tolerable up to 600mg/week in cancer patients when administered with meal and prophylactic antiemetics." | 2.75 | First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ( Berdel, W; Engel, J; Hanauske, AR; Mross, K; Sindermann, H; Unger, C, 2010) |
| "Perifosine is an orally applicable, membrane-targeted alkylphosphocholine analogue with antitumour activity and radiosensitising properties in preclinical models." | 2.72 | Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. ( Bartelink, H; Beijnen, JH; Dubbelman, R; Engel, J; Hillebrand, MJ; Moppi, G; Schellens, JH; Sindermann, H; Verheij, M; Vink, SR, 2006) |
| "Perifosine (NSC 639966) is a synthetic, substituted heterocyclic alkylphosphocholine that acts primarily at the cell membrane targeting signal transduction pathways." | 2.71 | A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. ( Alberti, D; Arzoomanian, R; Binger, K; Kolesar, J; Marnocha, R; Tutsch, K; Van Ummersen, L; Volkman, J; Wilding, G, 2004) |
| "Many types of cancer, for example glioblastoma, show resistance against current anti-cancer treatments." | 2.50 | Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment. ( Gavish, M; Kugler, W; Veenman, L, 2014) |
| "Perifosine treatment exhibits a complex molecular response including the inhibition of Akt or the induction of apoptosis via clustering of death receptors in lipid rafts." | 2.50 | Current view on the mechanism of action of perifosine in cancer. ( Aicher, B; Engel, J; Fensterle, J; Seipelt, I; Teifel, M, 2014) |
| "Perifosine is an oral Akt inhibitor currently being tested in phase 2 clinical trials." | 2.45 | Perifosine: update on a novel Akt inhibitor. ( Dennis, PA; Gills, JJ, 2009) |
| "Synthetic anticancer alkylphospholipids (APLs), such as edelfosine, miltefosine and perifosine, are a group of structurally related lipids that act on cellular membranes rather than the DNA." | 2.44 | Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. ( van Blitterswijk, WJ; Verheij, M, 2008) |
| "Synthetic alkylphospholipids are anticancer agents that in contrast to most anticancer drugs, do not target DNA, but insert in the plasma membrane and subsequently induce a broad range of biological effects, ultimately leading to cell death." | 2.44 | Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. ( Schellens, JH; van Blitterswijk, WJ; Verheij, M; Vink, SR, 2007) |
| "The experience of treating cancer over the past several decades overwhelmingly demonstrates that the disease continues to evade the vast array of drugs and treatment modalities available in the twenty-first century." | 2.42 | Choline phospholipid metabolism: a target in cancer cells? ( Ackerstaff, E; Bhujwalla, ZM; Glunde, K, 2003) |
| "In a clinical phase I trial on breast cancer patients with local recurrences, topically applied He-PC resulted in regression of skin metastases." | 2.38 | Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug. ( Eibl, H; Unger, C, 1991) |
| "Choline is an essential nutrient for mammalian cells." | 1.72 | Metabolic Labeling-Based Chemoproteomics Establishes Choline Metabolites as Protein Function Modulators. ( Dixit, A; Jose, GP; Kalia, J; Shanbhag, C; Tagad, N, 2022) |
| "Hemolysis is a serious side effect of antitumor alkylphospholipids (APLs) that limits dose levels and is a constraint in their use in therapeutic regimen." | 1.56 | Synthesis and Evaluation of Antitumor Alkylphospholipid Prodrugs. ( Gaillard, B; Lebeau, L; Pons, F; Remy, JS, 2020) |
| "However, in mouse orthotopic xenograft tumors, zwitterionic PMPC-based polyplexes showed highest in vivo luciferase silencing (>75% knockdown for 10 days with single IV 1 mg/kg dose) and 3-fold higher average tumor cell uptake than 5 kDa PEG polyplexes (20 kDa PEG polyplexes were only 2-fold higher than 5 kDa PEG)." | 1.46 | Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol. ( Curvino, EJ; Dockery, MD; Duvall, CL; Giorgio, TD; Jackson, AN; Jackson, MA; Kavanaugh, TE; Kilchrist, KV; Sarett, SM; Werfel, TA; Yu, F, 2017) |
| "In a murine cancer model, the PMPC conjugate completely inhibited tumor growth and cured 75% mice, whereas at the same dose, no mice treated with interferon-alpha or PEGASYS survived." | 1.43 | In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy. ( Gao, W; Hu, J; Wang, G; Zhao, W, 2016) |
| "Perifosine did reduce primary breast cancer orthotopic xenograft tumor size, but did not impact metastatic burden in a statistically significant manner." | 1.42 | Perifosine as a potential novel anti-telomerase therapy. ( Friedman, DR; Hagiopian, MM; Holohan, B; Huang, E; Lai, TP; Shay, JW; Wright, WE, 2015) |
| "Many solid tumors contain an overabundance of phospholipid ethers relative to normal cells." | 1.40 | Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. ( Chen, HE; Clark, PA; Clarke, W; Farhoud, M; Floberg, JM; Grudzinski, J; Hall, LT; Kandela, IK; Kuo, JS; Longino, MA; Pazoles, CJ; Pickhardt, PJ; Pinchuk, AN; Swanson, KI; Titz, B; Traynor, AM; Vaccaro, AM; Weichert, JP, 2014) |
| "Akt is activated in most human cancers and contributes to cell growth, proliferation and cellular survival pathway." | 1.39 | Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines. ( Alam, MM; Joh, EH; Kim, B; Kim, DH; Lee, YS; Park, H, 2013) |
| "Metabolic changes observed in various cancer cell lines and tumors have been associated with differential and marked up-regulation of the CKα genes, and specific inhibition of CKα activity has been proposed as a potential anti-cancer strategy." | 1.38 | Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy. ( Gruber, J; Konrad, M; Lavie, A; McSorley, T; See Too, WC; Wong, MT, 2012) |
| "It is critical to develop methods to quantify the early pharmacodynamic effects of targeted therapeutics in vivo to make drug development more efficient and ensure biologically relevant dosing." | 1.34 | Pharmacodynamic markers of perifosine efficacy. ( Birch, R; Carey, MS; Gonzalez-Angulo, AM; Hall, H; Henderson, IC; Hennessy, BT; Kundra, V; Lu, Y; Mills, GB; Poradosu, E; Ravoori, M; Yu, Q; Yu, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.69) | 18.7374 |
| 1990's | 8 (13.56) | 18.2507 |
| 2000's | 16 (27.12) | 29.6817 |
| 2010's | 25 (42.37) | 24.3611 |
| 2020's | 9 (15.25) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 3 |
| Wang, Y | 2 |
| Xin, Q | 1 |
| Li, M | 1 |
| Yu, P | 1 |
| Luo, J | 1 |
| Xu, X | 1 |
| Chen, X | 1 |
| Li, J | 2 |
| Dixit, A | 1 |
| Jose, GP | 1 |
| Shanbhag, C | 1 |
| Tagad, N | 1 |
| Kalia, J | 1 |
| Baghdasaryan, A | 1 |
| Wang, F | 1 |
| Ren, F | 1 |
| Ma, Z | 1 |
| Zhou, X | 1 |
| Grigoryan, L | 1 |
| Xu, C | 1 |
| Dai, H | 1 |
| Geng, H | 1 |
| Lin, W | 1 |
| Liu, J | 4 |
| Pei, Q | 1 |
| Xie, Z | 1 |
| Gu, X | 1 |
| Zhang, R | 1 |
| Sun, Y | 1 |
| Ai, X | 1 |
| Lyu, Y | 1 |
| Wang, X | 1 |
| Wu, Y | 1 |
| Wang, Z | 1 |
| Feng, N | 1 |
| Liu, Y | 3 |
| Munakata, L | 1 |
| Tanimoto, Y | 1 |
| Osa, A | 1 |
| Meng, J | 1 |
| Haseda, Y | 1 |
| Naito, Y | 1 |
| Machiyama, H | 1 |
| Kumanogoh, A | 1 |
| Omata, D | 1 |
| Maruyama, K | 1 |
| Yoshioka, Y | 1 |
| Okada, Y | 1 |
| Koyama, S | 1 |
| Suzuki, R | 1 |
| Aoshi, T | 1 |
| Wu, Z | 2 |
| Chen, B | 1 |
| Gan, Z | 1 |
| Chen, F | 1 |
| Luo, X | 2 |
| Li, L | 2 |
| Song, Y | 1 |
| He, J | 1 |
| Zhang, M | 1 |
| Ni, P | 1 |
| Gaillard, B | 1 |
| Remy, JS | 1 |
| Pons, F | 1 |
| Lebeau, L | 1 |
| Jiang, S | 1 |
| Wang, W | 2 |
| Dong, L | 1 |
| Yan, X | 1 |
| Li, S | 1 |
| Mei, W | 1 |
| Xie, X | 1 |
| Liu, S | 2 |
| Yu, X | 2 |
| Yang, M | 1 |
| Li, C | 1 |
| Jackson, MA | 1 |
| Werfel, TA | 1 |
| Curvino, EJ | 1 |
| Yu, F | 1 |
| Kavanaugh, TE | 1 |
| Sarett, SM | 1 |
| Dockery, MD | 1 |
| Kilchrist, KV | 1 |
| Jackson, AN | 1 |
| Giorgio, TD | 1 |
| Duvall, CL | 1 |
| Ou, H | 1 |
| Cheng, T | 1 |
| Ding, Y | 1 |
| Zhen, J | 1 |
| Shen, W | 1 |
| Xu, Y | 1 |
| Yang, W | 1 |
| Niu, P | 1 |
| An, Y | 1 |
| Shi, L | 1 |
| Logue, JS | 1 |
| Cartagena-Rivera, AX | 1 |
| Chadwick, RS | 1 |
| Cai, M | 1 |
| Li, Y | 1 |
| Cao, J | 1 |
| Chen, Y | 1 |
| Zhang, RR | 1 |
| Grudzinksi, JJ | 1 |
| Mehta, TI | 1 |
| Burnette, RR | 1 |
| Hernandez, R | 1 |
| Clark, PA | 2 |
| Lubin, JA | 1 |
| Pinchuk, AN | 2 |
| Jeffrey, J | 1 |
| Longino, M | 1 |
| Kuo, JS | 2 |
| Weichert, JP | 2 |
| Alam, MM | 1 |
| Joh, EH | 1 |
| Park, H | 1 |
| Kim, B | 1 |
| Kim, DH | 1 |
| Lee, YS | 1 |
| Wnętrzak, A | 1 |
| Lątka, K | 1 |
| Dynarowicz-Łątka, P | 1 |
| Veenman, L | 1 |
| Gavish, M | 1 |
| Kugler, W | 1 |
| Fensterle, J | 1 |
| Aicher, B | 1 |
| Seipelt, I | 1 |
| Teifel, M | 1 |
| Engel, J | 3 |
| Oyama, T | 1 |
| Takeuchi, H | 1 |
| Matsuda, S | 1 |
| Ozawa, S | 1 |
| Kitajima, M | 1 |
| Kitagawa, Y | 1 |
| Kandela, IK | 1 |
| Vaccaro, AM | 1 |
| Clarke, W | 1 |
| Longino, MA | 1 |
| Farhoud, M | 1 |
| Swanson, KI | 1 |
| Floberg, JM | 1 |
| Grudzinski, J | 1 |
| Titz, B | 1 |
| Traynor, AM | 1 |
| Chen, HE | 1 |
| Hall, LT | 1 |
| Pazoles, CJ | 1 |
| Pickhardt, PJ | 1 |
| Figg, WD | 1 |
| Monga, M | 1 |
| Headlee, D | 1 |
| Shah, A | 1 |
| Chau, CH | 1 |
| Peer, C | 1 |
| Messman, R | 1 |
| Elsayed, YA | 1 |
| Murgo, AJ | 1 |
| Melillo, G | 1 |
| Ryan, QC | 1 |
| Kalnitskiy, M | 1 |
| Senderowicz, AM | 1 |
| Hollingshead, M | 1 |
| Arbuck, SG | 1 |
| Sausville, EA | 1 |
| Falcon, SC | 1 |
| Hudson, CS | 1 |
| Huang, Y | 1 |
| Mortimore, M | 1 |
| Golec, JM | 1 |
| Charlton, PA | 1 |
| Weber, P | 1 |
| Sundaram, H | 1 |
| Holohan, B | 1 |
| Hagiopian, MM | 1 |
| Lai, TP | 1 |
| Huang, E | 1 |
| Friedman, DR | 1 |
| Wright, WE | 1 |
| Shay, JW | 1 |
| Wang, B | 1 |
| Ma, X | 1 |
| Shang, X | 1 |
| Hu, J | 1 |
| Wang, G | 1 |
| Zhao, W | 1 |
| Gao, W | 1 |
| Jiang, H | 1 |
| Chen, D | 1 |
| Guo, D | 1 |
| Wang, N | 1 |
| Su, Y | 1 |
| Jin, X | 1 |
| Tong, G | 1 |
| Zhu, X | 1 |
| van Blitterswijk, WJ | 3 |
| Verheij, M | 4 |
| Gills, JJ | 1 |
| Dennis, PA | 1 |
| Cseh, A | 1 |
| Szebeni, B | 1 |
| Szalay, B | 1 |
| Vásárhelyi, B | 1 |
| Gallego-Ortega, D | 1 |
| Ramirez de Molina, A | 1 |
| Ramos, MA | 1 |
| Valdes-Mora, F | 1 |
| Barderas, MG | 1 |
| Sarmentero-Estrada, J | 1 |
| Lacal, JC | 1 |
| Unger, C | 4 |
| Berdel, W | 1 |
| Hanauske, AR | 1 |
| Sindermann, H | 2 |
| Mross, K | 1 |
| Plano, D | 1 |
| Baquedano, Y | 1 |
| Moreno-Mateos, D | 1 |
| Font, M | 1 |
| Jiménez-Ruiz, A | 1 |
| Palop, JA | 1 |
| Sanmartín, C | 1 |
| Miki, K | 1 |
| Kimura, A | 1 |
| Oride, K | 1 |
| Kuramochi, Y | 1 |
| Matsuoka, H | 1 |
| Harada, H | 1 |
| Hiraoka, M | 1 |
| Ohe, K | 1 |
| Gruber, J | 1 |
| See Too, WC | 1 |
| Wong, MT | 1 |
| Lavie, A | 1 |
| McSorley, T | 1 |
| Konrad, M | 1 |
| Ho, WL | 1 |
| Wong, H | 1 |
| Yau, T | 1 |
| Crul, M | 1 |
| Rosing, H | 1 |
| de Klerk, GJ | 1 |
| Dubbelman, R | 2 |
| Traiser, M | 1 |
| Reichert, S | 1 |
| Knebel, NG | 1 |
| Schellens, JH | 3 |
| Beijnen, JH | 2 |
| ten Bokkel Huinink, WW | 1 |
| BURSELL, S | 1 |
| NAESLUND, G | 1 |
| NAESLUND, J | 1 |
| SWENSON, KE | 1 |
| Ackerstaff, E | 1 |
| Glunde, K | 1 |
| Bhujwalla, ZM | 1 |
| Aoyama, C | 1 |
| Liao, H | 1 |
| Ishidate, K | 1 |
| Arias-Mendoza, F | 1 |
| Zakian, K | 1 |
| Schwartz, A | 1 |
| Howe, FA | 1 |
| Koutcher, JA | 1 |
| Leach, MO | 1 |
| Griffiths, JR | 1 |
| Heerschap, A | 1 |
| Glickson, JD | 1 |
| Nelson, SJ | 1 |
| Evelhoch, JL | 1 |
| Charles, HC | 1 |
| Brown, TR | 1 |
| Van Ummersen, L | 1 |
| Binger, K | 1 |
| Volkman, J | 1 |
| Marnocha, R | 1 |
| Tutsch, K | 1 |
| Kolesar, J | 1 |
| Arzoomanian, R | 1 |
| Alberti, D | 1 |
| Wilding, G | 1 |
| Knowling, M | 1 |
| Blackstein, M | 1 |
| Tozer, R | 1 |
| Bramwell, V | 1 |
| Dancey, J | 1 |
| Dore, N | 1 |
| Matthews, S | 1 |
| Eisenhauer, E | 1 |
| Vink, SR | 2 |
| Moppi, G | 1 |
| Hillebrand, MJ | 1 |
| Bartelink, H | 1 |
| Hennessy, BT | 1 |
| Lu, Y | 1 |
| Poradosu, E | 1 |
| Yu, Q | 1 |
| Yu, S | 1 |
| Hall, H | 1 |
| Carey, MS | 1 |
| Ravoori, M | 1 |
| Gonzalez-Angulo, AM | 1 |
| Birch, R | 1 |
| Henderson, IC | 1 |
| Kundra, V | 1 |
| Mills, GB | 1 |
| Mintz, A | 1 |
| Wang, L | 1 |
| Ponde, DE | 1 |
| Hilgard, P | 2 |
| Klenner, T | 1 |
| Stekar, J | 2 |
| Bhakoo, KK | 1 |
| Williams, SR | 1 |
| Florian, CL | 1 |
| Land, H | 1 |
| Noble, MD | 1 |
| Grunicke, HH | 1 |
| Maly, K | 1 |
| Uberall, F | 1 |
| Schubert, C | 1 |
| Kindler, E | 1 |
| Brachwitz, H | 1 |
| Moxon, ER | 1 |
| Wills, C | 1 |
| Podo, F | 1 |
| Eibl, H | 2 |
| Redmond, OM | 1 |
| Bell, E | 1 |
| Stack, JP | 1 |
| Dervan, PA | 1 |
| Carney, DN | 1 |
| Hurson, B | 1 |
| Ennis, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma[NCT02278315] | Phase 1 | 31 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma[NCT00053794] | Phase 2 | 17 participants (Actual) | Interventional | 2003-06-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for phosphorylcholine and Neoplasms
| Article | Year |
|---|---|
Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Membrane; Erucic Acids; Glioblastom | 2014 |
Current view on the mechanism of action of perifosine in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Humans; Lipid Metabolism | 2014 |
Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Transport; Clinical Trials as Topic; Combined | 2008 |
Perifosine: update on a novel Akt inhibitor.
Topics: Animals; Clinical Trials as Topic; Humans; Membrane Microdomains; Neoplasms; Phosphorylcholine; Prot | 2009 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizot | 2013 |
Anticancer mechanisms and clinical application of alkylphospholipids.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Endocytosis; Humans; Neoplasms; O | 2013 |
Choline phospholipid metabolism: a target in cancer cells?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Choline Kinase; En | 2003 |
Structure and function of choline kinase isoforms in mammalian cells.
Topics: Amino Acid Sequence; Animals; Cell Division; Choline; Choline Kinase; Humans; Isomerism; Liver; Mamm | 2004 |
Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies.
Topics: Biomarkers, Tumor; Ethanolamines; Humans; Internationality; Magnetic Resonance Spectroscopy; Multice | 2004 |
Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Neoplasms; Phospholipid Ethers; Phosphoryl | 2007 |
Alkylphosphocholines: a new class of membrane-active anticancer agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation | 1993 |
Tumour phospholipid metabolism.
Topics: Animals; Ethanolamines; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Phosphatidylcholines; Ph | 1999 |
[Drug development from phospholipids].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Drug De | 2001 |
Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug.
Topics: Adult; Aged; Antineoplastic Agents; Cell Division; Cell Line; Drug Screening Assays, Antitumor; Fema | 1991 |
7 trials available for phosphorylcholine and Neoplasms
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Area Under Curve; Diarrhea; Disease | 2014 |
First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
Topics: Abdominal Pain; Administration, Oral; Antiemetics; Antineoplastic Agents; Diarrhea; Dose-Response Re | 2010 |
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; | 2002 |
Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies.
Topics: Biomarkers, Tumor; Ethanolamines; Humans; Internationality; Magnetic Resonance Spectroscopy; Multice | 2004 |
A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Drug Administra | 2004 |
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Canada; Disease Progression; Female; H | 2006 |
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hum | 2006 |
39 other studies available for phosphorylcholine and Neoplasms
| Article | Year |
|---|---|
Zwitterionic choline phosphate conjugated folate-poly (ethylene glycol): a general decoration of erythrocyte membrane-coated nanoparticles for enhanced tumor-targeting drug delivery.
Topics: Erythrocyte Membrane; Folic Acid; Humans; Nanoparticles; Neoplasms; Phosphorylcholine; Polyethylene | 2022 |
Metabolic Labeling-Based Chemoproteomics Establishes Choline Metabolites as Protein Function Modulators.
Topics: Animals; Antineoplastic Agents; Choline; Humans; Mammals; Neoplasms; Phosphorylcholine; Proteome | 2022 |
Phosphorylcholine-conjugated gold-molecular clusters improve signal for Lymph Node NIR-II fluorescence imaging in preclinical cancer models.
Topics: Animals; Coloring Agents; Fluorescence; Gold; Indocyanine Green; Lymph Nodes; Mice; Neoplasms; Optic | 2022 |
Choline phosphate lipid-hitchhiked near-infrared BODIPY nanoparticles for enhanced phototheranostics.
Topics: Boron; Humans; Lipids; Nanoparticles; Neoplasms; Optical Imaging; Phosphorylcholine | 2023 |
Oral membrane-biomimetic nanoparticles for enhanced endocytosis and regulation of tumor-associated macrophage.
Topics: Animals; Biomimetics; Cell Line, Tumor; Mice; Nanoparticles; Neoplasms; Phosphorylcholine; Tumor Mic | 2023 |
Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice.
Topics: Animals; Antineoplastic Agents; Blood Cells; CD8-Positive T-Lymphocytes; Drug Compounding; Drug Stab | 2019 |
Exogenous Vitamin C-Triggered Surface Charge Conversion of pH/Reduction-Responsive Micelles for the Enhanced Tumor-Specific Activity of Loaded Doxorubicin.
Topics: Allografts; Animals; Antineoplastic Agents; Ascorbic Acid; Cell Survival; Disease Models, Animal; Do | 2020 |
Zwitterionic shielded polymeric prodrug with folate-targeting and pH responsiveness for drug delivery.
Topics: Doxorubicin; Drug Delivery Systems; Drug Liberation; Folic Acid; HeLa Cells; Humans; Hydrogen-Ion Co | 2019 |
Synthesis and Evaluation of Antitumor Alkylphospholipid Prodrugs.
Topics: Administration, Intravenous; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitum | 2020 |
Infrared Responsive Choline Phosphate Lipids for Synergistic Cancer Therapy.
Topics: Doxorubicin; Drug Liberation; Lipids; Nanoparticles; Neoplasms; Phosphorylcholine | 2021 |
Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; | 2021 |
Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Female; Humans; Male; Mice, Nude; Nanostructures; Neoplasm | 2017 |
Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells.
Topics: Animals; Antineoplastic Agents; Blood Circulation Time; Drug Delivery Systems; HEK293 Cells; Hep G2 | 2018 |
c-Src activity is differentially required by cancer cell motility modes.
Topics: Actins; Amino Acid Substitution; Butadienes; Cell Adhesion; Cell Movement; Dasatinib; Humans; Imidaz | 2018 |
Bioinspired mimics: Self-assembly of redox-activated phosphorylcholine-based biodegradable copolymers for enhancing antitumor efficiency.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Drug Li | 2018 |
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Lipoproteins; Mice; Mice, Nude; Models, Biologi | 2019 |
Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines.
Topics: Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans | 2013 |
Interactions of alkylphosphocholines with model membranes-the Langmuir monolayer study.
Topics: Animals; Cell Membrane; Cholesterol; Humans; Neoplasms; Phosphatidylcholines; Phosphorylcholine; Uni | 2013 |
Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-Paclitaxel conjugate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cell Line, Tumor; Cell Survival; Disease Mo | 2014 |
Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Mice; Neoplasms; Phosphorylcholine | 2014 |
A non-catalytic role of choline kinase alpha is important in promoting cancer cell survival.
Topics: Cell Survival; Choline Kinase; HeLa Cells; Humans; Neoplasms; Phosphorylcholine; RNA, Small Interfer | 2013 |
Perifosine as a potential novel anti-telomerase therapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; | 2015 |
Tailor-Made pH-Responsive Poly(choline phosphate) Prodrug as a Drug Delivery System for Rapid Cellular Internalization.
Topics: A549 Cells; Cell Survival; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; | 2016 |
In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Female; Humans; Interferon-alpha | 2016 |
Zwitterionic gold nanorods: low toxicity and high photothermal efficacy for cancer therapy.
Topics: Animals; Cell Line, Tumor; Cetrimonium; Cetrimonium Compounds; Gold; Humans; Hyperthermia, Induced; | 2017 |
[Akt enzyme: new therapeutic target in cancer and diabetes?].
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Diabetes Mellitus; Enzyme Activ | 2009 |
Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.
Topics: Alternative Splicing; Animals; Cell Line, Tumor; Cell Membrane; Choline Kinase; Dogs; Ethanolamines; | 2009 |
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
Topics: Aminophenols; Animals; Antiprotozoal Agents; Cell Line, Tumor; Cyanates; Humans; Inhibitory Concentr | 2011 |
High-contrast fluorescence imaging of tumors in vivo using nanoparticles of amphiphilic brush-like copolymers produced by ROMP.
Topics: Animals; Fluorescence; Fluorescent Dyes; Mice; Nanoparticles; Neoplasms; Phosphorylcholine; Polyethy | 2011 |
Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy.
Topics: Apoptosis; Cell Cycle; Choline Kinase; Gene Expression Regulation, Neoplastic; Gene Silencing; HeLa | 2012 |
ACCESS oncology and Zentaris sign product partnership.
Topics: Clinical Trials, Phase II as Topic; Cooperative Behavior; Drug Industry; Humans; Neoplasms; Phosphor | 2002 |
Investigations of malignant tumours with radioactive phosphocholine.
Topics: Choline; Humans; Neoplasms; Phosphorylcholine; Radioactivity | 1953 |
Pharmacodynamic markers of perifosine efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relat | 2007 |
Comparison of radiolabeled choline and ethanolamine as probe for cancer detection.
Topics: Carbon Radioisotopes; Cell Line, Tumor; Choline; Ethanolamine; Ethanolamines; Fibroblasts; Fluorine | 2008 |
Immortalization and transformation are associated with specific alterations in choline metabolism.
Topics: Animals; Antigens, Viral, Tumor; Cell Division; Cell Line, Transformed; Choline; Glioblastoma; Human | 1996 |
Cellular signalling as a target in cancer chemotherapy. Phospholipid analogues as inhibitors of mitogenic signal transduction.
Topics: Antineoplastic Agents; Calcium; Enzyme Inhibitors; Inositol 1,4,5-Trisphosphate; Molecular Structure | 1996 |
DNA microsatellites: agents of evolution?
Topics: Adaptation, Physiological; Animals; Bacteria; Bacterial Outer Membrane Proteins; Base Pairing; Base | 1999 |
Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo 31P magnetic resonance spectroscopy.
Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Adjuvant; Ethanolamines; Female; Glycerylphosphorylcholin | 1992 |
New pharmaceuticals: miltefosine.
Topics: Animals; Antineoplastic Agents; Mammary Neoplasms, Experimental; Neoplasms; Phosphorylcholine | 1990 |